RLYB - Rallybio Collaborating with J&J to Advance Therapeutic Solutions for Pregnant Individuals at Risk of FNAIT

2024-04-11 07:37:24 ET

DENVER, Colo., Apr 11, 2024 ( 247marketnews.com )- Rallybio Corporation (NASDAQ: RLYB ) stated that it’s collaborating with Johnson & Johnson to develop complementary therapeutic approaches that reduce the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

The agreement includes a $6.6 million equity investment from Johnson & Johnson Innovation to Rallybio, which is developing RLYB212, a novel human monoclonal anti-HPA-1a antibody designed to prevent pregnant individuals from alloimmunizing, thereby eliminating the risk of FNAIT and its potentially devastating consequences in their fetuses and newborns.

“We are thrilled to be working with Johnson & Johnson on our mission to eliminate FNAIT,” said Stephen Uden, M.D., Chief Executive Officer of Rallybio. “Our complementary approaches, if successful, would ensure that pregnant individuals at risk of developing FNAIT have a potential treatment option – regardless of their alloimmunization status. Together, we can more effectively and expeditiously drive awareness of FNAIT, emphasize the importance of screening pregnant individuals for their risk of developing FNAIT, and advance our complementary therapeutic approaches.”

The post Rallybio Collaborating with J&J to Advance Therapeutic Solutions for Pregnant Individuals at Risk of FNAIT appeared first on 24/7 MarketNews .

For further details see: